217 related articles for article (PubMed ID: 33906306)
1. Development of Escherichia coli asparaginase II for the Treatment of Acute Lymphocytic Leukemia: In Silico Reduction of asparaginase II Side Effects by a Novel Mutant (V27F).
Ardalan N; Akhavan Sepahi A; Khavari-Nejad RA
Asian Pac J Cancer Prev; 2021 Apr; 22(4):1137-1147. PubMed ID: 33906306
[TBL] [Abstract][Full Text] [Related]
2. Novel mutant of Escherichia coli asparaginase II to reduction of the glutaminase activity in treatment of acute lymphocytic leukemia by molecular dynamics simulations and QM-MM studies.
Ardalan N; Mirzaie S; Sepahi AA; Khavari-Nejad RA
Med Hypotheses; 2018 Mar; 112():7-17. PubMed ID: 29447943
[TBL] [Abstract][Full Text] [Related]
3. In silico engineering of L-asparaginase to have reduced glutaminase side activity for effective treatment of acute lymphoblastic leukemia.
Ln R; Doble M; Rekha VP; Pulicherla KK
J Pediatr Hematol Oncol; 2011 Dec; 33(8):617-21. PubMed ID: 22042278
[TBL] [Abstract][Full Text] [Related]
4. Rational engineering and insight for a L-glutaminase activity reduced type II L-asparaginase from Bacillus licheniformis and its antileukemic activity in vitro.
Zhou Y; Shen J; Chi H; Zhu X; Lu Z; Lu F; Zhu P
Int J Biol Macromol; 2024 Feb; 257(Pt 2):128690. PubMed ID: 38092107
[TBL] [Abstract][Full Text] [Related]
5. Glutaminase Activity of L-Asparaginase Contributes to Durable Preclinical Activity against Acute Lymphoblastic Leukemia.
Chan WK; Horvath TD; Tan L; Link T; Harutyunyan KG; Pontikos MA; Anishkin A; Du D; Martin LA; Yin E; Rempe SB; Sukharev S; Konopleva M; Weinstein JN; Lorenzi PL
Mol Cancer Ther; 2019 Sep; 18(9):1587-1592. PubMed ID: 31209181
[TBL] [Abstract][Full Text] [Related]
6. Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Oncology Group study (CCG-1941).
Jarrar M; Gaynon PS; Periclou AP; Fu C; Harris RE; Stram D; Altman A; Bostrom B; Breneman J; Steele D; Trigg M; Zipf T; Avramis VI
Pediatr Blood Cancer; 2006 Aug; 47(2):141-6. PubMed ID: 16425271
[TBL] [Abstract][Full Text] [Related]
7. Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961).
Panosyan EH; Grigoryan RS; Avramis IA; Seibel NL; Gaynon PS; Siegel SE; Fingert HJ; Avramis VI
Anticancer Res; 2004; 24(2C):1121-5. PubMed ID: 15154634
[TBL] [Abstract][Full Text] [Related]
8. A clinically attainable dose of L-asparaginase targets glutamine addiction in lymphoid cell lines.
Sugimoto K; Suzuki HI; Fujimura T; Ono A; Kaga N; Isobe Y; Sasaki M; Taka H; Miyazono K; Komatsu N
Cancer Sci; 2015 Nov; 106(11):1534-43. PubMed ID: 26331698
[TBL] [Abstract][Full Text] [Related]
9. In Silico Design of a Chimeric Humanized L-asparaginase.
Pedroso A; Herrera Belén L; Beltrán JF; Castillo RL; Pessoa A; Pedroso E; Farías JG
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108713
[TBL] [Abstract][Full Text] [Related]
10. Mutations in subunit interface and B-cell epitopes improve antileukemic activities of Escherichia coli asparaginase-II: evaluation of immunogenicity in mice.
Mehta RK; Verma S; Pati R; Sengupta M; Khatua B; Jena RK; Sethy S; Kar SK; Mandal C; Roehm KH; Sonawane A
J Biol Chem; 2014 Feb; 289(6):3555-70. PubMed ID: 24297177
[TBL] [Abstract][Full Text] [Related]
11. A protease-resistant Escherichia coli asparaginase with outstanding stability and enhanced anti-leukaemic activity in vitro.
Maggi M; Mittelman SD; Parmentier JH; Colombo G; Meli M; Whitmire JM; Merrell DS; Whitelegge J; Scotti C
Sci Rep; 2017 Nov; 7(1):14479. PubMed ID: 29101342
[TBL] [Abstract][Full Text] [Related]
12. Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models.
Avramis VI; Martin-Aragon S; Avramis EV; Asselin BL
Anticancer Res; 2007; 27(4C):2561-72. PubMed ID: 17695416
[TBL] [Abstract][Full Text] [Related]
13. L-Asparagine depletion levels and L-asparaginase activity in plasma of children with acute lymphoblastic leukemia under asparaginase treatment.
Tsurusawa M; Chin M; Iwai A; Nomura K; Maeba H; Taga T; Higa T; Kuno T; Hori T; Muto A; Yamagata M;
Cancer Chemother Pharmacol; 2004 Mar; 53(3):204-8. PubMed ID: 14634792
[TBL] [Abstract][Full Text] [Related]
14. Enzyme Engineering Strategies for the Bioenhancement of L-Asparaginase Used as a Biopharmaceutical.
Miranda J; Lefin N; Beltran JF; Belén LH; Tsipa A; Farias JG; Zamorano M
BioDrugs; 2023 Nov; 37(6):793-811. PubMed ID: 37698749
[TBL] [Abstract][Full Text] [Related]
15. Microbial production, molecular modification, and practical application of l-Asparaginase: A review.
Wang Y; Xu W; Wu H; Zhang W; Guang C; Mu W
Int J Biol Macromol; 2021 Sep; 186():975-983. PubMed ID: 34293360
[TBL] [Abstract][Full Text] [Related]
16. Cloning and characterization of Halomonas elongata L-asparaginase, a promising chemotherapeutic agent.
Ghasemi A; Asad S; Kabiri M; Dabirmanesh B
Appl Microbiol Biotechnol; 2017 Oct; 101(19):7227-7238. PubMed ID: 28801829
[TBL] [Abstract][Full Text] [Related]
17. Towards development of biobetter: L-asparaginase a case study.
Tripathy RK; Anakha J; Pande AH
Biochim Biophys Acta Gen Subj; 2024 Jan; 1868(1):130499. PubMed ID: 37914146
[TBL] [Abstract][Full Text] [Related]
18. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
Hawkins DS; Park JR; Thomson BG; Felgenhauer JL; Holcenberg JS; Panosyan EH; Avramis VI
Clin Cancer Res; 2004 Aug; 10(16):5335-41. PubMed ID: 15328169
[TBL] [Abstract][Full Text] [Related]
19. The glutaminase activity of L-asparaginase is not required for anticancer activity against ASNS-negative cells.
Chan WK; Lorenzi PL; Anishkin A; Purwaha P; Rogers DM; Sukharev S; Rempe SB; Weinstein JN
Blood; 2014 Jun; 123(23):3596-606. PubMed ID: 24659632
[TBL] [Abstract][Full Text] [Related]
20. Critical overview of the main features and techniques used for the evaluation of the clinical applicability of L-asparaginase as a biopharmaceutical to treat blood cancer.
Costa-Silva TA; Costa IM; Biasoto HP; Lima GM; Silva C; Pessoa A; Monteiro G
Blood Rev; 2020 Sep; 43():100651. PubMed ID: 32014342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]